Therapeutics Development Services

Seprase or fibroblast activation protein (FAP) has been identified as a prominent potential target for several tumor therapies. At Alfa Cytology, we establish multiple therapeutic strategies against seprase (FAP) while supporting research into innovative therapies for cancers, fibrotic diseases, and autoimmune disorders.

Introduction to Seprase (FAP)-Targeted Therapeutics

Seprase (FAP) is one such serine protease with dual enzymatic activity that is overexpressed in cancer-associated fibroblasts (CAFs) of breast, pancreatic, and other tumor types, while relatively little is expressed in other healthy adult tissues. Seprase (FAP) can modulate tumor growth in several ways: it can promote proliferation, invasion, angiogenesis, epithelial-to-mesenchymal transition, stem cell promotion, immunosuppression, and drug resistance.

Fig. 1 Potential signaling pathways affected by FAP that are responsible for the tumor promoting phenotypes associated with FAP expression. (Fitzgerald, A. A., et al. 2020)

Seprase (FAP)-Targeted Therapeutics Development

The following are therapeutic drug development that target seprase or fibroblast activation protein (FAP), including but not limited to:

Disclaimer: Alfa Cytology focuses on providing preclinical research service. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.

Our Services

Designed specifically for FAP-centered research, we offer a comprehensive range of important therapeutic drug developments. Operating on the principle of developing fibroblast-activating protein (FAP)-targeted therapeutics, we have developed a suite of services to support every step of the drug development process. At Alfa Cytology, our technical team, possessing vast expertise and capability, extends services enriched with knowledge and experience to clients in support of every step in the development of innovative therapeutic drugs.

Different Therapeutic Disease Areas

Different disease areas in which drug discovery services support and offer a full range of drug development.

Multiple Drug Development Platforms

We have a team of professionals specializing in various seprase (FAP)-Targeted drug development platforms and other state-of-the-art techniques.

In addition to establishing drug development service platforms for all types of seprase (FAP)-Targeted therapeutics, we have gathered numerous preclinical animal models and have put a lot of effort into global collaboration to advance the therapeutic research process.

Through scientific excellence and in-depth knowledge of seprase (FAP) biology, Alfa Cytology is poised to become a desirable partner for developing therapeutics targeted against FAP. Please contact us for further information about how our comprehensive range of services can successfully support your drug discovery and development program.

For research use only.